23.1 Health professionals and other relevant decision makers may be used as consultants and advisors, whether in groups or individually, for services such as speaking at and chairing meetings, involvement in medical/scientific studies, clinical trials or training services, participation at advisory board meetings, and participation in market research where such participation involves remuneration and/or travel. The arrangements which cover these genuine consultancy or other services must, to the extent relevant to the particular arrangement, fulfil all the following criteria:
23.2 Pharmaceutical companies must publicly disclose details of the fees paid to consultants in the UK, or to their employers on their behalf, for certain services rendered by them such as chairing and speaking at meetings, assistance with training and participation in advisory boards etc. It includes payments to consultants in relation to research and development work, including the conduct of clinical trials.
23.3 In addition to the information required to be made public by Clause 23.2, companies must publicly disclose details of payments made to consultants in relation to market research (unless the company concerned is not aware of the identities of those participating in the market research).
23.4 Fees, expenses and the like due to consultants in relation to Clauses 23.2 and 23.3 must be disclosed whether paid directly to them or to their employers or to healthcare organisations or to companies or charities etc.
Clause 23 The Use of ConsultantsThe term ‘consultant’ in Clause 23 covers any health professional or other relevant decision maker consulted for the purposes described in Clause 23 regardless of their normal roles.Other relevant decsion makers covered by Clause 23 are those who could influence in any way the prescription, supply, administration, recommendation, purchase or sale of any medicine.Clause 23 Patient OrganisationsThe provision of services to pharmaceutical companies by patient organisations is covered by Clause 27.8.Clause 23.1 The Use of ConsultantsThe requirement that contracts or agreements with consultants must include provisions regarding their obligation to declare the arrangement whenever they write or speak in public applies to contracts entered into or renewed on or after 1 May 2011. Companies are encouraged to renegotiate existing contracts to include such provisions at their earliest convenience.Limited market research, such as one-off telephone interviews or mail/email/Internet questionnaires was excluded from the scope of Clause 20.1 of the 2012 Code, provided that the consultant was not consulted in a recurring manner (either with respect to the frequency of the calls generally or of calls relating to the same research) and that the remuneration was minimal. Following implementation of Clause 20.3 of the 2012 Code, payments made in relation to this limited market research must be made publicly available in accordance with that clause.If health professionals or other relevant decision makers attend events in a consultant or advisory capacity the relevant provisions of Clause 22 apply.
Clause 23.2 DisclosureThe information required by Clause 23.2 must be publicly disclosed in respect of the calendar year 2015 and each calendar year thereafter.Disclosure must be carried out in accordance with Clause 24.The information which must be disclosed is the total amount paid in a calendar year to each consultant who has provided services. Companies may, of course, give greater detail, for example by giving separate figures for different categories of service.Fees and agreed expenses should be disclosed separately.The names of the consultants must be disclosed except in relation to payments in relation to research and development work, including clinical trials, as defined below, where disclosure should be on an aggregate basis.Clause 23.2 Research and Development Transfers of ValueFor the purpose of disclosure research and development transfers of value are transfers of value to health professionals or healthcare organisations related to the planning or conduct of:
Costs that are subsidiary to these activities can be included in the aggregate amount.
Clause 23.3 DisclosureClause 23.3 relates only to market research using consultants where the pharmaceutical company knows the identity of the consultants. This is because the focus of the requirements concerning transparency is on areas where there are direct relationships between the parties and that is not so where the company does not know the identity of the participants.Disclosure for Calendar Years 2013 and 2014For disclosures in relation to the calendar years 2013 and 2014, the requirements and procedures in Clauses 20.2 and 20.3 and their supplementary information in the Second 2012 Edition of the Code still apply.